Canada Venous Diseases Treatment Market Size, Share, and COVID-19 Impact Analysis, By Treatment Type (Surgeries, Angioplasty or Stenting, Vein Ligation and stripping, Vena Cava Filter, Ambulatory Phlebectomy, Therapies, Sclerotherapy, Radiofrequency Ablation Therapy, Laser Treatment, and Others), By Disease Type (Deep-vein Thrombophlebitis, Varicose Veins, Superficial Thrombophlebitis, Chronic Venous Insufficiency, Venous Ulcers, and Others), By Product Type (Ablation Devices, Venous Stents, Venous Closure Products, Sclerotherapy Injections, and Others), By End-User (Hospitals, Clinic, and Ambulatory Centers), and Canada Venous Diseases Treatment Market Insights Forecasts 2023 - 2033.

Canada Venous Diseases Treatment Market Insights Forecasts to 2033

• The Canada Venous Diseases Treatment Market Size is Growing at 5.7% CAGR from 2023 to 2033.
• The Canada Venous Diseases Treatment Market Size is Expected to Reach a Significant Share by 2033.

The Canada Venous Diseases Treatment Market Size is expected to reach a significant share by 2033, growing at a 5.7% CAGR from 2023 to 2033.     

Market Overview

The treatment market for venous diseases in Canada is the health sector in Canada that involves the diagnosis, management, and treatment of venous diseases. The conditions that are included under venous diseases are varicose veins, deep vein thrombosis (DVT), chronic venous insufficiency (CVI), spider veins, and venous ulcers. The Canada venous diseases treatment market is huge with increasing conditions such as varicose veins and deep vein thrombosis. Levels of awareness are on the rise, minimally invasive procedures are evolving, and an increased number of elderly individuals contribute to the demand for therapies such as sclerotherapy, laser therapy, and compression therapy. Increased healthcare units and technological advancements for vascular treatment drive market growth. Also, positive payment policies and higher uptake of aesthetic vein treatments represent profitable opportunities for healthcare providers and medical device firms. However, in January 2025, the government of Canada signed a bilateral agreement with Ontario, investing over $535 million to improve access to drugs for rare diseases.

Report Coverage

This research report categorizes the market for the Canada venous diseases treatment market based on various segments and regions forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada venous disease treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada venous diseases treatment market.

Driving Factors

The increasing incidence of venous conditions such as varicose veins, deep vein thrombosis (DVT), and chronic venous insufficiency (CVI) is one of the prime drivers. The trend of an aging population and higher obesity rates further increases the risk of venous disease, thereby increasing demand for treatment. Technological improvements in minimally invasive therapies, like laser therapy and radiofrequency ablation, are broadening the range of treatment possibilities. Growing patient awareness and better healthcare facilities are also driving the market. Moreover, access to sophisticated drugs, such as anticoagulants and sclerotherapy drugs, helps achieve better treatment. Government support in terms of reimbursement policies for venous disease treatments is also contributing to the growth of the market. Finally, a rising demand for outpatient treatments and cosmetic vein treatment is having a positive impact on the industry.

Restraining Factors

The Canada venous diseases treatment market is confronted with constraints such as the high cost of treatment, low insurance coverage, risks involved in surgical interventions, and a lack of specialized healthcare professionals. Furthermore, patient aversion to invasive treatments, low awareness of advanced therapies, and strict regulatory approvals are the constraints that impede market growth.

Market Segment

• The sclerotherapy segment held the greatest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the treatment type, the Canada venous diseases treatment market is divided into surgeries, angioplasty or stenting, vein ligation and stripping, vena cava filter, ambulatory phlebectomy, therapies, sclerotherapy, radiofrequency ablation therapy, laser treatment, and others. Among these, the sclerotherapy segment held the greatest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. This is because of its cost-effectiveness, least invasive procedure, high success rate in the treatment of varicose and spider veins, and rapid recovery period. Growing patient inclination towards outpatient treatments, rising incidence of venous diseases, and improvements in sclerosing agents also contribute to its growth over the forecast period.

• The varicose veins segment accounted for the majority of the share in 2023 and is estimated to grow at a significant CAGR during the projected timeframe.

Based on the disease type, the Canada venous diseases treatment market is divided into deep-vein thrombophlebitis, varicose veins, superficial thrombophlebitis, chronic venous insufficiency, venous ulcers, and others. Among these, the varicose veins segment accounted for the majority of the share in 2023 and is estimated to grow at a significant CAGR during the projected timeframe. This is due to the rising prevalence of obesity, the aging population, sedentary lifestyles, and prolonged standing jobs. Increasing awareness, technological advancements in treatment options, and growing demand for minimally invasive procedures further drive its significant CAGR during the projected timeframe.

• The sclerotherapy injections segment held the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the product type, the Canada venous diseases treatment market is divided into ablation devices, venous stents, venous closure products, sclerotherapy injections, and others. Among these, the sclerotherapy injections segment held the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. This is attributed to its minimally invasive procedure, cost-saving, and high success rate in addressing varicose and spider veins. The growing patient inclination for outpatient treatments, technological innovation in sclerosing agents, and enhanced awareness regarding the availability of non-surgical treatments further catalyze its strong growth in the forecast period.

• The hospitals segment accounted for the majority of the share in 2023 and is estimated to grow at a significant CAGR during the projected timeframe.

Based on the end-user, the Canada venous diseases treatment market is divided into hospitals, clinics, and ambulatory centers. Among these, the hospitals segment accounted for the majority of the share in 2023 and is estimated to grow at a significant CAGR during the projected timeframe. This is attributed to the presence of sophisticated treatment facilities, experienced medical professionals, and holistic patient care. Rising hospital admissions for the treatments of venous disease, increased healthcare infrastructure investments, and patients' preference towards specialized care fuel its high growth throughout the forecast period.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Canada venous diseases treatment market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Medtronic
• AngioDynamics
• Boson Scientific Corporation
• Alma Lasers
• Merit Medical Systems
• Sciton, Inc
• Teleflex Incorporated
• biolitec AG
• Dornier Medtech

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the Canada venous diseases treatment market based on the below-mentioned segments:

Canada Venous Diseases Treatment Market, By Treatment Type

• Surgeries
• Angioplasty or Stenting
• Vein Ligation and stripping
• Vena Cava Filter
• Ambulatory Phlebectomy
• Therapies
• Sclerotherapy
• Radiofrequency Ablation Therapy
• Laser Treatment, and Others

Canada Venous Diseases Treatment Market, By Disease Type

• Deep-vein Thrombophlebitis
• Varicose Veins
• Superficial Thrombophlebitis
• Chronic Venous Insufficiency
• Venous Ulcers
• Others

Canada Venous Diseases Treatment Market, By Product Type

• Ablation Devices
• Venous Stents
• Venous Closure Products
• Sclerotherapy Injection
• Others

Canada Venous Diseases Treatment Market, By End-User

• Hospitals
• Clinics
• Ambulatory Centers